Nolvadex (tamoxifen) and Arimidex (anastrozole) are both medications that reduce the effects of estrogen, and they are often discussed together. However, the comparison of Nolvadex vs Arimidex involves two drugs that work through completely different mechanisms, have different approved uses, and carry different risks.
Both were developed to treat breast cancer, and neither is approved in the United States for use in bodybuilding or after anabolic steroid use. This article explains how each drug works, what each is prescribed for, how their side effects differ, and why those differences matter.
What are Nolvadex and Arimidex?
Nolvadex (tamoxifen)
Tamoxifen is a selective estrogen receptor modulator (SERM). It does not lower estrogen levels. Instead, it binds to estrogen receptors and blocks estrogen’s effects in some tissues, such as breast tissue, while mimicking estrogen’s effects in others, such as bone and the lining of the uterus.
Arimidex (anastrozole)
Anastrozole is an aromatase inhibitor. Aromatase is the enzyme that converts androgens, including testosterone, into estrogens. By blocking this enzyme, anastrozole lowers the amount of estrogen the body produces.
The key difference
The simplest way to understand Nolvadex vs Arimidex is that tamoxifen changes how tissues respond to estrogen, while anastrozole reduces how much estrogen is present. This difference explains most of the contrasts in their effects and risks.
What are they approved to treat?
Both drugs are approved mainly for hormone receptor-positive breast cancer, a type of cancer whose growth is driven by estrogen.
Tamoxifen is used to treat breast cancer in women and men, and to reduce breast cancer risk in some women at high risk. It can be used before and after menopause.
Anastrozole is approved for postmenopausal women with hormone receptor-positive breast cancer. It is not effective as a stand-alone treatment before menopause, because the ovaries continue to produce estrogen.
Neither drug is approved in the United States to treat low testosterone in men. Doctors sometimes prescribe them off-label for specific conditions in men, such as certain cases of breast tissue enlargement (gynecomastia), under medical supervision.
How do they affect testosterone in men?
In men, estrogen is part of the feedback system that controls testosterone production. Estrogen signals to the hypothalamus and pituitary gland that hormone levels are sufficient, which reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Both drugs can interrupt this feedback, but in different ways:
Tamoxifen blocks estrogen receptors in the hypothalamus and pituitary, so the brain senses less estrogen and increases LH and FSH. This can raise testosterone levels while estrogen levels stay the same or rise.
Anastrozole lowers estrogen production, which also increases LH and testosterone. In a study of older men with low or borderline-low testosterone, anastrozole raised testosterone and lowered estradiol (Leder et al., 2004).
These effects explain why both drugs are discussed in the context of hormonal recovery after anabolic steroid use. However, recovery of natural testosterone production is complex and varies widely between individuals, as explained in our article on testosterone recovery after steroids. The use of these drugs for this purpose is not an approved indication and should not be attempted without medical supervision.
Why lowering estrogen too much is a problem for men
Estrogen is often described as a hormone to be minimized in men, but it has important functions. In men, estradiol contributes to bone health, sexual desire, and the regulation of body fat.
Research has shown that when estradiol production is suppressed in men, sexual desire can decline and body fat can increase, even when testosterone is maintained (Finkelstein et al., 2013). Our article on libido after steroids discusses estradiol’s role in sexual desire in more detail.
Bone is also affected. In a one-year trial in older men, anastrozole raised testosterone but led to a decrease in bone mineral density in the spine compared with placebo (Burnett-Bowie et al., 2009).
This is one of the most important differences between the two drugs. Because anastrozole lowers estrogen throughout the body, it carries a risk of reducing estrogen below the level men need. Tamoxifen does not lower estrogen levels in the same way.
How do their side effects differ?
Tamoxifen side effects
Common side effects of tamoxifen include hot flashes and nausea. More serious risks include blood clots in the veins or lungs and stroke. In women, tamoxifen also increases the risk of cancer of the uterus. These serious risks are highlighted in the drug’s prescribing information.
Anastrozole side effects
Common side effects of anastrozole include joint pain and stiffness, hot flashes, and fatigue. Because it lowers estrogen, it can also reduce bone density and increase the risk of osteoporosis and fractures, and it can affect cholesterol levels.
Why the differences matter
Each drug’s risks follow from how it works. Tamoxifen’s estrogen-like effects in some tissues contribute to its clotting and uterine risks, while anastrozole’s estrogen-lowering effect contributes to its bone and joint effects. Choosing between them for a medical condition is a clinical decision that depends on the condition being treated and the individual’s risk factors.
Are Nolvadex and Arimidex regulated?
In the United States, tamoxifen and anastrozole are prescription medications. They are not controlled substances, but they are approved only for specific medical uses and should be taken under the supervision of a healthcare professional.
In competitive sport, both selective estrogen receptor modulators and aromatase inhibitors are prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List (WADA, 2026).
The bottom line
The difference between Nolvadex vs Arimidex comes down to mechanism. Tamoxifen blocks estrogen’s effects at the receptor level without lowering estrogen, while anastrozole lowers estrogen production by blocking the aromatase enzyme. Both are approved mainly for treating hormone receptor-positive breast cancer.
Both drugs can raise testosterone in men by interrupting the hormonal feedback system, but they are not approved for that purpose. Anastrozole carries the additional risk of lowering estrogen below what men need for bone health and sexual function, while tamoxifen carries risks such as blood clots. Anyone considering either medication should do so only under the guidance of a qualified healthcare professional.
References
Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. Journal of Clinical Endocrinology & Metabolism. 2009;94(12):4785–4792.
Finkelstein JS, Lee H, Burnett-Bowie SM, et al. Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine. 2013;369(11):1011–1022.
Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. Journal of Clinical Endocrinology & Metabolism. 2004;89(3):1174–1180. World Anti-Doping Agency. The 2026 Prohibited List. World Anti-Doping Code International Standard.
